Navigation Links
Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors
Date:1/26/2012

SUNNYVALE, Calif., Jan. 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today publication of a study demonstrating the benefits of the CyberKnife® Robotic Radiosurgery System in treating central lung tumors. Historically, the treatment of central lung tumors using gantry based Stereotactic Body Radiotherapy (SBRT) has been challenging and required a great deal of accuracy to avoid risks of damaging critical structures, such as the airway, esophagus and heart that can result in serious complications including death, leaving patients with fewer, less effective and sometimes only palliative options. This study, published in the January 2012 online issue of Radiotherapy & Oncology (commonly known as the Green Journal), demonstrated that the CyberKnife System, which leverages the Synchrony® Respiratory Tracking System and Lung Optimized Treatment to non-invasively track and correct for respiratory motion, allows clinicians to deliver lung SBRT to patients with central lung lesions with minimal toxicity, sparing surrounding healthy tissue, such as the esophagus, trachea and heart while also providing high levels of tumor control.

The study, "Outcome of Four-Dimensional Stereotactic Radiotherapy for Centrally Located Lung Tumors," reports on 56 patients (39 with primary lung cancer and 17 with metastatic tumors) treated with CyberKnife lung SBRT who were ineligible for surgery or chemotherapy, refused surgery or chemotherapy, or had an inoperable tumor. Local tumor control was 91 percent for the entire group at one year and 76 percent for the entire group at two years. The analysis of toxicity rates demonstrated that there were no serious complications reporting no acute grade three esophagitis, no grade four (life threatening/disabling) or five (fatal) toxicities in the patients treated. 

"In this study, we were able to achieve two-year tumor control and overall survival for centrally located lung tumors comparable to what is generally reported for SBRT treatment of peripheral lung tumors without putting patients at risk for complications or serious toxicities," said Joost Nuyttens, M.D., Ph.D., at Erasmus MC - Daniel den Hoed Cancer Center in Rotterdam, The Netherlands and lead author of the study. "By taking advantage of the CyberKnife System's radiosurgical accuracy and image guidance capabilities, the Synchrony System allows us to track centrally located tumors as they move with respiration and correct for tumor motion throughout treatment. This allows us to deliver the high doses required to treat lung tumors without increasing the impact to surrounding healthy tissue, something that was difficult to do with gantry based SBRT systems."

"Traditionally, treating centrally located lung tumors with SBRT has been precarious given the proximity of these tumors to other critical structures. This has resulted in most centers and studies staying away from treating these patients using lung SBRT," said Omar Dawood, M.D., M.P.H., senior vice president of global medical affairs for Accuray. "This study from one of the world's leading research institutions provides further support of the CyberKnife System's ability to deliver lung SBRT to tumors throughout the lung, even centrally located tumors, with minimal toxicity while also providing excellent tumor control. These benefits offer renewed hope to patients who may not otherwise have had any other treatment options."

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company's technologies and more than 600 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to types of patient treatments, clinical objectives and clinical benefits are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: clinical effectiveness, range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2011 fiscal year, our form 10-Q filed on November 8, 2011 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

 

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D.
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

 

 


'/>"/>
SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... LONDON , Feb.8, 2016 Aesthetic Devices ... GlobalData,s Medical Devices sector report, "Aesthetic Devices - Medical ... Devices currently in pipeline stage. This ... secondary and primary research by GlobalData,s team of industry ... be removed or altered based on the availability and ...
(Date:2/8/2016)... , Feb. 8, 2016 CBG ... the PW Series Solvent Recycling Systems, specifically designed ... full integration with new and existing vapor degreasers, ... produces consistently-fresh solvent through continuous recycling and recovers ... --> --> Precision parts ...
(Date:2/8/2016)... 8, 2016  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... fourth quarter and year-end 2015 results after the Nasdaq ... then host a live conference call and webcast to ... Thursday afternoon, February 11, 2016 at 4:30 p.m. Eastern ... --> http://www.neurocrine.com . --> Participants ...
Breaking Medicine Technology:
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 ... in honor of his birthday on February 10th. During this time, people can ... known by over 250,000 people from over 40 different countries as an “ordinary man ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to ... the U.S. require dental technicians to be certified or obtain continuing education. To ... created the “What’s In Your Mouth?” campaign to inform dentists and patients about ...
(Date:2/7/2016)... Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... in recognition of National Wear Red Day. National Wear Red Day is the ... stroke in women. Heart disease and stroke cause 1 in 3 deaths among women ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd Hobgood ... his medical and surgical expertise. Technically known as deoxycholic acid or previously as ... a non-surgical alternative for reduction of fat below the chin (aka the “double ...
Breaking Medicine News(10 mins):